Beijing Konruns Pharmaceutical Co.,Ltd. is a high-tech enterprise focused on the research, development, manufacturing, and commercialization of pharmaceutical products within China. The company is publicly traded on the Shanghai Stock Exchange, having been listed in August 2018. Its primary offerings include Viburnum hemagglutinin, marketed as Suling, a pioneering hemocoagulase preparation utilized to manage bleeding during and after surgical procedures. Beyond this, the firm provides products like Migexin salmon calcitonin nasal spray and Migasil salmon calcitonin injection. Konruns is actively advancing a robust pipeline of innovative and generic drug candidates, particularly in the fields of oncology and blood-related disorders, with several compounds such as CX1026, CX1003, KC1036, and KC1086 undergoing clinical trials for various advanced solid tumors and other conditions. The company, established in 2003, is headquartered in Beijing, China, and reported operating revenue of 692 million yuan for the first three quarters of 2025.